Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

被引:540
|
作者
Basso, AD
Solit, DB
Chiosis, G
Giri, B
Tsichlis, P
Rosen, N
机构
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Thomas Jefferson Univ, Kimmel Canc, Philadelphia, PA 19107 USA
[4] Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, Philadelphia, PA 19107 USA
关键词
D O I
10.1074/jbc.M206322200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hsp90 is a chaperone required for the conformational maturation of certain signaling proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small molecules that bind to the ATP-binding pocket in the amino-terminal domain of Hsp90 inhibit its function and cause the degradation of these client proteins. Inhibition of Hsp90 function in cells causes down-regulation of an Akt kinase-dependent pathway required for D-cyclin expression and retinoblastoma protein-dependent G, arrest. Intracellular Akt is associated with Hsp90 and Cdc37 in a complex in which Akt kinase is active and regulated by phosphatidylinositol 3-kinase. Functional Hsp90 is required for the stability of Akt in the complex. Occupancy of the ATP-binding pocket by inhibitors is associated with the ubiquitination of Akt and its targeting to the proteasome, where it is degraded. This results in a shortening of the half-life of Akt from 36 to 12 h and an 80% reduction in its expression. Akt and its activating kinase, PDK1, are the only members of the protein kinase A/protein kinase B/protein kinase C-like kinase family that are affected by Hsp90 inhibitors. Thus, transduction of growth factor signaling via the Akt and Raf pathways requires functional Hsp90 and can be coordinately blocked by its inhibition.
引用
收藏
页码:39858 / 39866
页数:9
相关论文
共 50 条
  • [41] Protein Kinase Recognition and Sorting by the HSP90 Kinome-Specific Cochaperone CDC37
    Gelis, Ioannis
    Keramisanou, Dimitra
    Aboalroub, Adam
    BIOPHYSICAL JOURNAL, 2017, 112 (03) : 491A - 491A
  • [42] Reactive cysteines of the 90-kDa heat shock protein, Hsp90
    Nardai, G
    Sass, B
    Eber, J
    Orosz, G
    Csermely, P
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 384 (01) : 59 - 67
  • [43] Potential role of heat shock protein 90 (Hsp90) in HIV uncoating
    Pheroze Joshi
    Cheryl A Stoddart
    Retrovirology, 8 (Suppl 2)
  • [44] Drug discovery and research of heat shock protein 90 (Hsp90) inhibitor
    Soga, Shiro
    Nakashima, Takayuki
    Ishii, Toshihiko
    Shiotsu, Yukimasa
    Akinaga, Shiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 26P - 26P
  • [45] Cytokine mediated regulation of heat shock protein 90 (Hsp90) and steroid receptor function
    Hasan, R. J.
    Ameredes, B. T.
    Calhoun, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S120 - S120
  • [46] Macrocyclic Inhibitors of Hsp90
    Johnson, Victoria A.
    Singh, Erinprit K.
    Nazarova, Lidia A.
    Alexander, Leslie D.
    McAlpine, Shelli R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (14) : 1380 - 1402
  • [47] Inhibitors of HSP90 in melanoma
    Aleksandra Mielczarek-Lewandowska
    Mariusz L. Hartman
    Malgorzata Czyz
    Apoptosis, 2020, 25 : 12 - 28
  • [48] Better HSP90 inhibitors
    Harrison Charlotte
    Nature Reviews Drug Discovery, 2013, 12 (5) : 346 - 346
  • [49] Inhibitors of HSP90 in melanoma
    Mielczarek-Lewandowska, Aleksandra
    Hartman, Mariusz L.
    Czyz, Malgorzata
    APOPTOSIS, 2020, 25 (1-2) : 12 - 28
  • [50] HSP90 and its inhibitors
    Hao, Huifang
    Naomoto, Yoshio
    Bao, Xiaohong
    Watanabe, Nobuyuki
    Sakurama, Kazufumi
    Noma, Kazuhiro
    Motoki, Takayuki
    Tomono, Yasuko
    Fukazawa, Takuya
    Shirakawa, Yasuhiro
    Yamatsuji, Tomoki
    Matsuoka, Junji
    Takaoka, Munenori
    ONCOLOGY REPORTS, 2010, 23 (06) : 1483 - 1492